EBS News and Press, Emergent Biosolutions Inc. From 01/27/21

Humanigen ([[HGEN]] +0.5%) and Ajinomoto Bio-Pharma Services announce that the companies will be expanding their manufacturing agreement for the fill finish supply of lenzilumab, a Phase 3 treatment option in development for patients hospitalized with COVID-19.Humanigen is actively enrolling ...

Emergent BioSolutions (EBS) and Humanigen (HGEN) have entered into a contract development and manufacturing ((CDMO)) services agreement to accelerate the drug product manufacturing of lenzilumab, to prevent and treat an immune hyper-response called “cytokine storm.”Emergent...

Emergent BioSolutions Inc. (NYSE:EBS) (Emergent) and Humanigen, Inc. (NASDAQ:HGEN) (Humanigen) today announced that they have entered into a contract development and manufacturing (CDMO) services agreement to accelerate the drug product manufacturing of lenzilumab™, an an...

Emergent BioSolutions remains well insulated from peers, with key COVID-19 vaccine drivers and exposure to adjacent specialty markets in public crises prevention. Additional drivers in contract manufacturing continue to present for the company, which should contribute to revenue volum...

IQVIA demonstrates a strong sequential growth pattern, in near recovery to pre-pandemic volumes. Management have reinstated the buyback program, with ~$1 billion in authorization, and look set on acquisition targeting across FY2021. We feel shares are worth ~$197 at this point, an...

OraSure is well positioned to capture additional market share in DNA at-home testing and molecular collection device sales. The company offers differentiated propositions with unique exposure to the genome, microbiome and Covid-19 testing. Sequential growth patterns quarter/quarte...

Top executives at the COVID-19 vaccine developer Novavax (NVAX) have sold approximately $46M worth of company stock since the start of 2020, Reuters reported following a review of the company’s regulatory filings.As the Novavax shares rose nearly 3,000 times during the y...

Emergent BioSolutions (EBS) announces its financial forecast for 2021 and preliminary 2020 results.Total revenues for 2020 are expected to be in the range of $1,545M and $1,555M compared to prior guidance of $1,520M - $1,580M.Net Income of $295M - $310M vs. prior guidance of $255M - $285M.Adj...

Expects continued strong financial and operating momentum in 2021, forecasting total revenues of $2 billion at the midpoint and Adjusted EBITDA of $780 million at the midpoint, both increases year-over-year Reports preliminary 2020 total revenues of $1.55 billion at the midpoint and A...

Vaxart as a COVID-19 vaccine play had surged after upbeat news in June, but is now at lower valuations. Still, the stock price is on a net one-year uptrend, as a result of the biotech's quite unique treatment being developed against the coronavirus. Moreover, the company's image h...